ARTA
TARA icon

A.R.T. Advisors’s Protara Therapeutics TARA Stock Holding History

A.R.T. Advisors’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-321
Closed -$32K – 1740
2018
Q1 		$32K Sell
321
-70
-18% -$6.37K ﹤0.01% 1426
2017
Q4 		$29K Sell
391
-27
-6% -$2.17K ﹤0.01% 1304
2017
Q3 		$33K Buy
418
+8
+2% +$458 ﹤0.01% 1276
2017
Q2 		$25K Sell
410
-658
-62% -$36.9K ﹤0.01% 1335
2017
Q1 		$74K Buy
+1,068
New +$79.8K ﹤0.01% 1306

Other funds holding TARA

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DVC
Deer VII & Co Larchmont, New York $317M AUM 30.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

A.R.T. Advisors's TARA Position: Q2 2018 in Review

A.R.T. Advisors sold out of Protara Therapeutics (TARA) in Q2 2018, closing a stake of 321 shares — an estimated $32K sold.

A.R.T. Advisors first reported a position in TARA in Q1 2017 and held it in 5 quarters. The position peaked at $74K in Q1 2017. 25 funds tracked by Wall St. Rank hold TARA as of Q2 2018.

  • A.R.T. Advisors reported no remaining Protara Therapeutics position as of Q2 2018 after selling out during the quarter.
  • A.R.T. Advisors sold 321 Protara Therapeutics shares in Q2 2018, an estimated $32K.
  • A.R.T. Advisors first reported a position in Protara Therapeutics in Q1 2017 and held it in 5 quarters.
  • A.R.T. Advisors's Protara Therapeutics position peaked at $74K in Q1 2017.
  • 25 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2018.

Based on A.R.T. Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.